Healthcare · 13.15

Pharmaceutical R&D Services

Quantified news impact based on deduplicated, quality-reviewed events in a single 60-day window.

Average net impact+21weighted per event

Average gross impact21absolute weighted average

Events7same period

Confidence70%model average

Raw intensity51before weighting

Previous period0net impact

Gross changeInsufficient base

Diffusion speed0.1 / day

Concentration17%

Direction disagreement200%

Source independence100%6 sources

IMPACT TREND

60-day effective impact

Positive 7 · Negative 0 · Mixed 0

+190-19

3 Jun0 events

8 Jun0 events

13 Jun0 events

18 Jun0 events

23 Jun0 events

28 Jun0 events

3 Jul0 events

8 Jul0 events

13 Jul0 events

18 Jul0 events

+18

23 Jul5 events

+19

28 Jul2 events

Current periodPrevious period

TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact

Short term0%0 cumulative effective impact

Medium term52%79 cumulative effective impact

Long term48%71 cumulative effective impact

CO-IMPACT

Related industries

EVENT EVIDENCE

Events ranked by effective impact

Page 1 of 1 · 7 events

Macro0

No evidence on this page.

Industries3

Industries29 Jul, 21:00positive

China's Innovative Drug Out-Licensing Hits 81 Deals ~$110 Billion in H1 2026; 38 Class 1 Drugs Approved

In the first half of 2026, China's innovative drug out-licensing reached 81 deals valued at about $110 billion, already 80% of the full-year 2025 total. Meanwhile, 38 Class 1 innovative drugs were approved for market, including 11 with new targets and mechanisms, all domestically developed. Chinese companies accounted for eight of the top ten global pharmaceutical deals, and total deal value represented about 70% of global M&A. The period also saw the first AI-discovered drug enter Phase III trials in China.

Effective: +33
Intensity: 60
Confidence: 70%
Horizon: Long term

Industries27 Jul, 19:09positive

CDE Releases Pioneer Plan to Promote Organoid-Based Alternatives in Drug R&D

China's Center for Drug Evaluation released a draft 'Pioneer Plan' to promote new alternative methods (NAMs) such as organoids and organ-on-chip in drug development. The plan aims to reduce reliance on animal testing, which is costly, slow, and limited in human extrapolation. Traditional CROs are pivoting: Joinn expands into organoid platforms, Medicilon builds an AI-driven NAMs service, and Insilico Medicine develops automated liver organoid screening. Shanghai-based Yaosu Technology expects 2026 revenue in the tens of millions of yuan with over 100 million yuan in orders, having completed nearly 400 million yuan in Series A financing. The CDE targets producing guidance documents within two years.

Effective: +32
Intensity: 75
Confidence: 70%
Horizon: Medium term

Industries27 Jul, 21:15positive

China Issues TCM Revitalization Plan; Drug Registration Approvals and Medical Services Index Surge 4%

A-share medical services index rose over 4% on July 27 as multiple drug firms, including ST Wanbang, received registration certificates. Wanbang Pharmaceutical surged over 13%, while several other stocks gained over 6%. The National Administration of Traditional Chinese Medicine and the National Development and Reform Commission issued the 15th Five-Year Plan for TCM revitalization, covering the 2026-2030 period.

Effective: +17
Intensity: 45
Confidence: 70%
Horizon: Long term

Companies4

Companies29 Jul, 20:16positive

Haikou, Mindray Sign Strategic Agreement to Build Global Bonded Maintenance, Training, and Production Base

The Haikou municipal government and Shenzhen Mindray Bio-Medical Electronics Co. , Ltd. (Mindray Medical) have signed a strategic cooperation agreement to jointly build a global bonded maintenance center, a global training center, a high-end medical device production base, a digital-intelligent medical innovation system, and a regional testing center in Haikou. The collaboration is intended to enhance the medical device industry and healthcare innovation in the region.

Effective: +27
Intensity: 60
Confidence: 70%
Horizon: Medium term

Companies27 Jul, 21:29positive

Kelun-Biotech’s Dual-Load ADC Drug SKB565 Approved for Clinical Trials in Advanced Solid Tumors

Kelun-Biotech, a controlled subsidiary, has received clinical trial approval from the National Medical Products Administration’s Center for Drug Evaluation for its novel dual-load antibody-drug conjugate (ADC) SKB565, intended for advanced solid tumors. This is the first dual-load ADC drug from Kelun-Biotech to enter the clinical stage.

Effective: +20
Intensity: 50
Confidence: 70%
Horizon: Medium term

Companies27 Jul, 17:13positive

China Biopharmaceutical and Tempo Scan Form Indonesia JV, China Holds 51% Stake

China Biopharmaceutical has signed a joint venture agreement with Indonesia-listed Tempo Scan to establish PT Tempo CTTQ Biopharmaceutical Indonesia (TCBI). China Biopharmaceutical holds a 51% stake, with Tempo Scan holding 49%. TCBI will combine Tempo Scan's local expertise with China Biopharmaceutical's R&D strengths to focus on drug registration, clinical development, and commercialization. Several products have received local regulatory approval or are under review, with the first specialty drugs expected to launch after regulatory clearance and operational preparations.

Effective: +19
Intensity: 45
Confidence: 80%
Horizon: Long term

Companies27 Jul, 18:43positive

Apeloa's Ante Yutai, WuXi Biologics, Duoning Sign Five-Year Strategic Framework without Specific Projects

Apeloa Pharmaceutical's controlled subsidiary Zhejiang Ante Yutai Biotechnology has signed a five-year strategic cooperation framework agreement with WuXi Biologics and Shanghai Duoning Biotechnology. The partnership aims to advance biopharmaceutical pipeline development, build industrialization capacity, and improve the supply chain. The agreement does not specify projects or amounts and will not materially affect the company's current fiscal year results.

Effective: +3
Intensity: 20
Confidence: 60%
Horizon: Long term